The document discusses the use of RBTs within a tiered service delivery model to improve clinical processes and outcomes. Data is presented showing that after introducing RBTs, there was an increase in the frequency and duration of interventions, more efficient data entry, and reductions in challenging behaviors and increases in skill acquisition for two individuals. The inclusion of RBTs allowed for more clinical presence in programs and improved clinical workflow. Overall, initial results indicate a favorable return on investment from using RBTs within the tiered model.
Second and third generation antipsychoticsDr Wasim
SECOND & THIRD GENERATION ANTIPSYCHOTIC mechanism of actionmechanism of side effectmanagment of side effect BY DR WASIM UNDERGUIDANCE OF DR SANJAY JAIN
First generation=typical antipsychoticaka conventionalprimary pharmacological property of D2 antagonistSecond generation=atypical antipsychoticlow EPS and good for negative symptomsThird generation=aripiprazole metabolic friendly
MECHANISM OF ACTION
1) serotonin dopamine antagonists
4)serotonin partial agonist
MECHANISM OF SIDE EFFECT
Serotonin-2C, muscarinic-3, and histamine-1 receptors as well as receptors X
identified are all hypothetically linked to cardiometabolic risk.
antagonism of serotonin-2C and histamine-1 receptors is associated with weight gain, while antagonism atmuscarinic-3 receptors can impair insulin regulation.
An unknown receptor X may be involved in the rapid production of insulin resistance and may also rapidly cause elevated fasting plasma triglyceride levels in some patients who experience increased cardiometabolic risk on certain atypical antipsychotics
Atypical antipsychotic and risk for weight gain.FDA and experts agree on three tiers of risk
Atypical antipsychotic and cardiometabolic risk.FDA and experts disagree on one versus three teirs of risk
Metabolic friendly antipsychotic.Low- risk agents for weight gain and cardiacmetabolic illness.
Monitoring and Managment
Baseline investigations :
Family h/o diabetes
BMI
Fasting TG levels (also monitored throughout treatment)
If raised : consider switching to another agent +/- lifestyle changes
For obese/ prediabetic/ diabetic pts :
Monitor BP
Fasting glucose
Waist circumference (before and after Rx)
Be vigilant for DKA/HHS
Sedation
ARIPIPRAZOLE KNOWN AS THIRD GENERATION ANTIPSYCHOTIC
THANK YOU
Second and third generation antipsychoticsDr Wasim
SECOND & THIRD GENERATION ANTIPSYCHOTIC mechanism of actionmechanism of side effectmanagment of side effect BY DR WASIM UNDERGUIDANCE OF DR SANJAY JAIN
First generation=typical antipsychoticaka conventionalprimary pharmacological property of D2 antagonistSecond generation=atypical antipsychoticlow EPS and good for negative symptomsThird generation=aripiprazole metabolic friendly
MECHANISM OF ACTION
1) serotonin dopamine antagonists
4)serotonin partial agonist
MECHANISM OF SIDE EFFECT
Serotonin-2C, muscarinic-3, and histamine-1 receptors as well as receptors X
identified are all hypothetically linked to cardiometabolic risk.
antagonism of serotonin-2C and histamine-1 receptors is associated with weight gain, while antagonism atmuscarinic-3 receptors can impair insulin regulation.
An unknown receptor X may be involved in the rapid production of insulin resistance and may also rapidly cause elevated fasting plasma triglyceride levels in some patients who experience increased cardiometabolic risk on certain atypical antipsychotics
Atypical antipsychotic and risk for weight gain.FDA and experts agree on three tiers of risk
Atypical antipsychotic and cardiometabolic risk.FDA and experts disagree on one versus three teirs of risk
Metabolic friendly antipsychotic.Low- risk agents for weight gain and cardiacmetabolic illness.
Monitoring and Managment
Baseline investigations :
Family h/o diabetes
BMI
Fasting TG levels (also monitored throughout treatment)
If raised : consider switching to another agent +/- lifestyle changes
For obese/ prediabetic/ diabetic pts :
Monitor BP
Fasting glucose
Waist circumference (before and after Rx)
Be vigilant for DKA/HHS
Sedation
ARIPIPRAZOLE KNOWN AS THIRD GENERATION ANTIPSYCHOTIC
THANK YOU
Mechanism of Action
300-3000 fold selectivity to block 5-HT >NE reuptake.
Receptors: M, α & H (little blockade)
Uses:
Depression (1st line of treatment of MDD )
Anxiety disorders (GAD, OCD, Panic, …..)
Eating Disorders e.g. Bulimia nervosa, Anorexia Nervosa
Preventing TB infection in HIV-infected
individuals living in medium and high TB endemic
settings
February 5, 2016
Jeffrey D. Jenks, MD, MPH
UCSD HIV & Global Health Rounds
- Were you diagnosed with colon or rectal cancer before the age of 50?
- Was anyone in your family diagnosed with colon cancer before the age of 50?
- Was anyone in your family diagnosed with uterine (endometrial) cancer before the age of 50?
- Are there cancers across several generations on one side of your family?
If you answered YES to just one of these questions, it's time to talk turkey about Lynch syndrome.
Lynch syndrome is an inherited genetic mutation, and having it increases your chance of getting colorectal cancer to 80%. Unfortunately, nearly every person living with Lynch syndrome is completely unaware of it.
Lynch syndrome also puts you at higher risk for brain, breast, kidney, melanoma, ovarian, pancreas, small bowel, stomach, or uterine/endometrial cancers. Knowledge is power and will help your medical team act more aggressively with their screening measures.
Brian Mansfield, a music critic for USA Today, didn't know he had Lynch syndrome until he was diagnosed with colorectal cancer earlier this year at the age of 48. After his diagnosis, he began talking with his family about their health history, "then the family tree lit up like a Christmas tree." Brian is chronicling his journey through a weekly USA Today online column, "My Semicolon Life."
Join national patient advocacy group Fight Colorectal Cancer as we host Brian and his doctor, Dr. Bill Harb, a colorectal surgeon at Cumberland Surgical Associates, along with Associate Director of Human Genetics at Ohio State University Heather Hampel as they tell you more about Lynch syndrome and how to dig into the medical mystery that may be lurking within your family tree. With the holidays coming up, never has there been a more appropriate time to talk turkey...and Lynch syndrome.
**Fight Colorectal Cancer thanks Can't Stomach Cancer, the Colon Club, Kidney Cancer Association, Myriad Genetics, and Ovarian Cancer National Alliance for their assistance with this webinar.**
Drug Abuse & Misuse, Sedative-Hypnotics “Benzodiazepines”Asra Hameed
Benzodiazepine abuse is a growing problem and carries serious risks to health and society.
Benzodiazepines are commonly used by polydrug abusers, alcoholics and sometimes as primary recreational drugs.
People who abuse benzodiazepines often take very large doses orally, by injection or by snorting.
Benzodiazepine use leads to dependence and a withdrawal syndrome which may include convulsions and psychosis.
Further research is needed on the optimal short-term and long-term management of benzodiazepine abuse.
The primary source of illicit benzodiazepines is from doctors' prescriptions.
INTRODUCTION
Dissociative Disorders are a group of conditions defined as psychological
disturbances that impact an individual’s ability to function and closely
overlap with psychotic disorders.
These include disturbances affecting:
Memory
Motor Control
Concept of Identity
Behaviours
Emotions
Perceptions
The symptoms of a dissociative disorder usually first develop as a
response to a traumatic event, such as abuse or military combat, to
keep those memories under control.
Stressful situations can worsen symptoms and cause problems with
functioning in everyday activities.
However, the symptoms a person experiences will depend on the
type of dissociative disorder that a person has.
TYPES OF DISSOCIATIVE DISORDER
DSM-5
Dissociative Identity Disorder (DID)
Dissociative Amnesia (Fugue)
Depersonalization/ Derealization Disorder
Other Specified Dissociative Disorder
Unspecified Dissociative Disorder
ICD-10
Dissociative Amnesia
Dissociative Fugue
Dissociative Stupor
Trance and Possession Disorders
Dissociative Motor Disorders
Dissociative Convulsions
Dissociative Anaesthesia and Sensory Loss
Mixed Dissociative (Conversion) Disorders
Other Dissociative (Conversion) Disorders:-
Ganser Syndrome
Multiple Personality
Psychogenic: Confusion and Twilight State
Dissociative (Conversion) Disorder
Dissociative Amnesia
Dissociative amnesia involves not being able to recall information about
oneself (not normal forgetting).
Dissociative amnesia is associated with having experiences of
childhood trauma, and particularly with experiences of emotional
abuse and emotional neglect.
The main symptom is memory loss that's more severe than normal
forgetfulness and that can't be explained by a medical condition.
Dissociative amnesia can be specific to events in a certain time, such
as intense combat, or more rarely, can involve complete loss of
memory about yourself.
This amnesia is usually related to a traumatic or stressful event and may be:
Localized: inability to remember all events occurring during a circumscribed
period of time.
Selective: inability to remember specific events occurring during a
circumscribed period of time.
Generalized: loss of memory encompasses everything, including one’s
identity.
Continuous: inability to recall events subsequent to a specific point in time
through the present.
Systematized: inability to recall memories related to a certain category of
information, e.g. memories related to an individual’s father.
Dissociative fugue (formerly called psychogenic fugue) is a psychological
state in which a person loses awareness of their identity or other important
autobiographical information and also engages in some form of unexpected
travel.
People who experience a dissociative fugue may suddenly find themselves
in a place, such as the beach or at work, with no memory of travelling
there.
The DSM-5 refers to dissociative fugue as a state of “bewildered
wandering.”
Dissociative Fugue
Formerly known as Mul
Mechanism of Action
300-3000 fold selectivity to block 5-HT >NE reuptake.
Receptors: M, α & H (little blockade)
Uses:
Depression (1st line of treatment of MDD )
Anxiety disorders (GAD, OCD, Panic, …..)
Eating Disorders e.g. Bulimia nervosa, Anorexia Nervosa
Preventing TB infection in HIV-infected
individuals living in medium and high TB endemic
settings
February 5, 2016
Jeffrey D. Jenks, MD, MPH
UCSD HIV & Global Health Rounds
- Were you diagnosed with colon or rectal cancer before the age of 50?
- Was anyone in your family diagnosed with colon cancer before the age of 50?
- Was anyone in your family diagnosed with uterine (endometrial) cancer before the age of 50?
- Are there cancers across several generations on one side of your family?
If you answered YES to just one of these questions, it's time to talk turkey about Lynch syndrome.
Lynch syndrome is an inherited genetic mutation, and having it increases your chance of getting colorectal cancer to 80%. Unfortunately, nearly every person living with Lynch syndrome is completely unaware of it.
Lynch syndrome also puts you at higher risk for brain, breast, kidney, melanoma, ovarian, pancreas, small bowel, stomach, or uterine/endometrial cancers. Knowledge is power and will help your medical team act more aggressively with their screening measures.
Brian Mansfield, a music critic for USA Today, didn't know he had Lynch syndrome until he was diagnosed with colorectal cancer earlier this year at the age of 48. After his diagnosis, he began talking with his family about their health history, "then the family tree lit up like a Christmas tree." Brian is chronicling his journey through a weekly USA Today online column, "My Semicolon Life."
Join national patient advocacy group Fight Colorectal Cancer as we host Brian and his doctor, Dr. Bill Harb, a colorectal surgeon at Cumberland Surgical Associates, along with Associate Director of Human Genetics at Ohio State University Heather Hampel as they tell you more about Lynch syndrome and how to dig into the medical mystery that may be lurking within your family tree. With the holidays coming up, never has there been a more appropriate time to talk turkey...and Lynch syndrome.
**Fight Colorectal Cancer thanks Can't Stomach Cancer, the Colon Club, Kidney Cancer Association, Myriad Genetics, and Ovarian Cancer National Alliance for their assistance with this webinar.**
Drug Abuse & Misuse, Sedative-Hypnotics “Benzodiazepines”Asra Hameed
Benzodiazepine abuse is a growing problem and carries serious risks to health and society.
Benzodiazepines are commonly used by polydrug abusers, alcoholics and sometimes as primary recreational drugs.
People who abuse benzodiazepines often take very large doses orally, by injection or by snorting.
Benzodiazepine use leads to dependence and a withdrawal syndrome which may include convulsions and psychosis.
Further research is needed on the optimal short-term and long-term management of benzodiazepine abuse.
The primary source of illicit benzodiazepines is from doctors' prescriptions.
INTRODUCTION
Dissociative Disorders are a group of conditions defined as psychological
disturbances that impact an individual’s ability to function and closely
overlap with psychotic disorders.
These include disturbances affecting:
Memory
Motor Control
Concept of Identity
Behaviours
Emotions
Perceptions
The symptoms of a dissociative disorder usually first develop as a
response to a traumatic event, such as abuse or military combat, to
keep those memories under control.
Stressful situations can worsen symptoms and cause problems with
functioning in everyday activities.
However, the symptoms a person experiences will depend on the
type of dissociative disorder that a person has.
TYPES OF DISSOCIATIVE DISORDER
DSM-5
Dissociative Identity Disorder (DID)
Dissociative Amnesia (Fugue)
Depersonalization/ Derealization Disorder
Other Specified Dissociative Disorder
Unspecified Dissociative Disorder
ICD-10
Dissociative Amnesia
Dissociative Fugue
Dissociative Stupor
Trance and Possession Disorders
Dissociative Motor Disorders
Dissociative Convulsions
Dissociative Anaesthesia and Sensory Loss
Mixed Dissociative (Conversion) Disorders
Other Dissociative (Conversion) Disorders:-
Ganser Syndrome
Multiple Personality
Psychogenic: Confusion and Twilight State
Dissociative (Conversion) Disorder
Dissociative Amnesia
Dissociative amnesia involves not being able to recall information about
oneself (not normal forgetting).
Dissociative amnesia is associated with having experiences of
childhood trauma, and particularly with experiences of emotional
abuse and emotional neglect.
The main symptom is memory loss that's more severe than normal
forgetfulness and that can't be explained by a medical condition.
Dissociative amnesia can be specific to events in a certain time, such
as intense combat, or more rarely, can involve complete loss of
memory about yourself.
This amnesia is usually related to a traumatic or stressful event and may be:
Localized: inability to remember all events occurring during a circumscribed
period of time.
Selective: inability to remember specific events occurring during a
circumscribed period of time.
Generalized: loss of memory encompasses everything, including one’s
identity.
Continuous: inability to recall events subsequent to a specific point in time
through the present.
Systematized: inability to recall memories related to a certain category of
information, e.g. memories related to an individual’s father.
Dissociative fugue (formerly called psychogenic fugue) is a psychological
state in which a person loses awareness of their identity or other important
autobiographical information and also engages in some form of unexpected
travel.
People who experience a dissociative fugue may suddenly find themselves
in a place, such as the beach or at work, with no memory of travelling
there.
The DSM-5 refers to dissociative fugue as a state of “bewildered
wandering.”
Dissociative Fugue
Formerly known as Mul
Clinical Data Quality in Mozambique: A Comparative ExerciseJSI
Presentation for the American Public Health Association & Expo in Atlanta, GA. November 2017:
Ensuring that quality data are collected and reported to the Ministry of Health (MOH) is a priority in Mozambique as it is the foundation for the provision of quality health services. Since 2014, the Strategic Information Project in Mozambique (M-SIP) has provided technical assistance to MOH to conduct annual rounds of data quality assessments (DQA) in each province. Seven indicators were selected as part of the national DQA strategy. Each DQA had a quantitative and a system assessment component. The quantitative component includes tracing and verification of reported data, where recounted data is compared to data reported at three levels: health facility (HF), district, and province. M-SIP conducted all DQAs using the same methodology making the results comparable. After three consecutive national rounds, there is a clear trend of improvement, despite deviations remaining high. The regular, reinforcing nature of this activity and consistency of HF recommendations has had a positive impact on the data quality and results of the assessments. For example, the overall national deviation of the “patients active in ART” indicator decreased from 37% to 22% over the three-year period. The successful implementation of the DQA activity, as well as its unique, inclusive approach to promoting MOH ownership, has resulted in MOH recognition—at all levels—that DQA activities are crucial to future success. The M-SIP and MOH teams are now developing a more methodological approach to MOH staff empowerment, enabling fully independent MOH implementation of this activity while continuing to improve the quality of data.
The Basics of Monitoring, Evaluation and Supervision of Health Services in NepalDeepak Karki
This presentation has made to health workers who have more than two decades of experience of managing/implementing public health programs in Nepal, especially at district level and below.
COnverting an Academic Medical Center to NIAHO/ISO 9001: Charleston Area Medi...Wes Chapman
This is the first in a series looking at the motivations, methods and outcomes from our efforts at Charleston Area Medical Center (CAMC) to build a “best-in-class” patient centered quality management system (QMS) including accreditation via NIAHO/ISO 9001. These articles are designed to be quick reads, and capture the realities that we encountered in this quest.
1. Do RBTs™ Improve Quality?
Improving clinical process and
outcomes via expansions of the
behavior analytic tiered service-
delivery model
Jonathan Worcester, Ph.D., NCSP, BCBA-D
Trisha O’Connell, M.A., LMHC, BCBA
Corina Lugo, B.S., RBT
Joseph N. Ricciardi, Psy.D., ABPP, BCBA-D, CBIS
2. Rationale: Behavior analysts are routinely asked to provide presented
with the challenge of providing comprehensive treatment to
individuals and families with increasing clinical complexity and acuity.
The BACB’s newest credential—the Registered Behavior Technician™-
-offers an opportunity for behavior analysts to improve clinical
processes and outcomes, potentially while delivering services more
efficiently and at greater volume.
The bottom line: What is the return on investment of the RBT
credential? What value do RBT-credentialed providers offer relative
to processes? Outcomes?
Rationale
3. Our Vertical Team Structure
We use a tiered service-delivery
model to ensure that all aspects of
clinical service delivery are properly
directed, supervised, and supported.
Pairs level of professional
competence with level of care
(medical necessity).
Consistent with BACB’s vision of
behavior analytic service delivery
(BACB, 2014).
Cost effective, built for growth and
sustainability.
BCBA-D
BCBA
BCaBA
RBT
BCBA
RBT RBT
4. The RBT™ Credential
BACB Requirements
18 years of age
High school or equivalency
Criminal background/abuse
registry check
40 –hour RBT training
RBT competency assessment
RBT examination (New; 12/14/15)
Additional SHF Requirements
Associates or bachelors degree
(prefer psychology or special
education)
Prior direct care experience
Safety-Care™ Behavioral Safety
Training certified trainer
Career aspirations in behavior
analysis
www.bacb.com
5. A. Measurement
B. Assessment
C. Skill Acquisition
D. Behavior Reduction
E. Documentation and Reporting
Professional Conduct and Scope of Practice
The RBT™ Task List
www.bacb.com
6. Measurement
Processes
Frequency of Visits
Duration of Visits
Minutes of Behavior Data Entry (A-05)
Minutes of Challenging Behavior Data
Graphing (A-05)
Minutes of Skill Acquisition Data Entry (A-05)
Minutes of Graphing Skill Acquisition (A-05)
Frequency of Staff Reinforcement(C-03)
Minutes of Incidental Teaching (C-05)
Minutes of Antecedent Intervention (D-03)
Minutes of DR (D-04)
Minutes of De-Escalation (D-05)
Minutes of Crisis Management (D-06)
Outcomes
Target behavior reduction
Skill acquisition
Qualitative data from BCBA
Qualitative data from RBT
9. 0
20
40
60
80
100
Program A
Baseline
Program A
Intervention
Program B
Baseline
Program B
Intervention
Miinutes
Duration of Time Engaged
in A-5 By BACB Credential
BCBA RBT
0
20
40
60
80
100
Program A
Baseline
Program A
Intervention
Program B
Baseline
Program B
Intervention
Minutes
Duration of Time Engaged in
C-3, C-5, D-3, D-4 By BACB
Credential
BCBA RBT
10. 0
5
10
15
20
25
30
Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15
Frequency
Individual A: Mean Monthly Challenging Behavior Frequency
Verbal Outburst SIB Minor SIB Major Aggressive Outburst
1/12/15, 1/29/15, 3/18/15: Medication changes
Consistent presence
of RBT started May
2015
11. 0%
20%
40%
60%
80%
100%
Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15
PercentAccuracy
Individual A: Monthly Mean FCT Data
Requesting Preferred Requesting Attention Requesting Escape
Goal Line
Consistent presence of
RBT started May 2015
12. 0
10
20
30
40
50
60
Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15
Frequency
Individual B: Mean Monthly Challenging Behavior Frequency
Verbal Outburst Aggressive Outburst Self-injury
Consistent presence of
RBT started May 2015
13. 0%
20%
40%
60%
80%
100%
Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15
PercentAccuracy
Individual B: Monthly Mean FCT Data
Requesting Preferred Requesting Attention Requesting Break Task Completion
Consistent presence of
RBT started May 2015
Goal Line
14. Conclusions
The inclusion of the RBT™
within the SHF vertical team
structure yielded initial positive
outcomes relative to clinical
processes and outcomes.
The representative data
depicted here illustrate a
favorable clinical return on
investment that outweighs
prerequisite demands on the
vertical team (e.g., supervision,
technical assessment, payroll).
Processes:
Increased frequency and
duration of interventions
implemented within programs.
Improved data entry/graphing
efficiency
Outcomes:
Contributed to stable behavior
change over time (reduction,
acquisition).
15. Collateral Outcomes
(Quality Improvements)
Increased Clinical Presence in Programs
Multiple visits per week to programs.
Increased opportunities for modeling, coaching,
and discrete trial training procedures.
More opportunities for objective assessments of
environmental triggers, challenging behaviors,
teaching and reinforcement opportunities, and
preferences.
Implementation appears to have improved as a
result of the increase in clinical presence (relative
to overall implementation and for materials-
dependent interventions such as FCT).
Improved Clinical Workflow
Material s development and job aides
Frees up BCBA to perform higher level
duties and responsibilities (e.g., behavior
support plan development, staff training,
data analysis and decision making).
Efficient staff training (position required
prior direct care experience).
Improves contextual fit (Albin et al., 1996)
relative to staff training, data sheets, and
intervention planning.
16. Treatment integrity data
Duration of time study
Expansion to additional RBT™ task list items
Expansion to additional individuals and programs
Limitations & Next Steps
17. Albin, R. W., Luchysyn, J. M., Horner, R. H., & Flannery, K. B. (1996). Contextual fit
for behavioral support plans. In L. K. Koegel, R. L. Koegel, & G. Dunlap (Eds.).
Positive Behavioral Support: Including people with difficult behavior in the community
(pp. 81-98), Baltimore, MD: Paul H. Brookes Publishing Co.
Behavior Analyst Certification Board. (2014). Applied behavior analysis treatment of
autism spectrum disorder: Practice guidelines for healthcare funders and managers
(2nd ed.). Littleton, CO: Author. Retrieved from http://bacb.com/wp-
content/uploads/2015/07/ABA_Guidelines_for_ASD.pdf.
Registered Behavior Technician™ Overview. Retrieved from www.bacb.com/rbt.
Behavior Analyst Certification Board. (2013). Registered Behavior Technician™
(RBT™)Task List. Littleton, CO: Author. Retrieved from http://bacb.com/wp-
content/uploads/2015/05/RBT_Task_List.pdf.
References